On the article " Drugs targeting protease-activated receptor-4 improve the anti-thrombotic therapeutic window"

Affiliations

Comment

Pancras C Wong et al. Ann Transl Med. 2018 Feb.

. 2018 Feb;6(3):71.

doi: 10.21037/atm.2017.11.31.

No abstract available

Conflict of interest statement

Conflicts of Interest: PC Wong and J Yang are employees of Bristol-Myers Squibb.

Drugs targeting protease-activated receptor-4 improve the anti-thrombotic therapeutic window.
French SL, Hamilton JR. French SL, et al. Ann Transl Med. 2017 Dec;5(23):464. doi: 10.21037/atm.2017.09.10. Ann Transl Med. 2017. PMID: 29285497 Free PMC article. No abstract available.

1. Wong PC, Seiffert D, Bird JE, et al. Blockade of protease-activated receptor-4 (PAR4) provides robust antithrombotic activity with low bleeding. Sci Transl Med 2017;9. pii: eaaf5294. 10.1126/scitranslmed.aaf5294 - DOI - PubMed
1. French SL, Hamilton JR. Drugs targeting protease-activated receptor-4 improve the anti-thrombotic therapeutic window. Ann Transl Med 2017;5:464. 10.21037/atm.2017.09.10 - DOI - PMC - PubMed
1. Callejo MF, Colin J, Desmeules S, et al. Mutagenesis Studies Reveal Minimal Impact of the Human A120T Variant of Protease-activated Receptor 4 on Receptor Function or Pharmacological Response to Potent and Selective Antagonists. Stroke 2016;47:AWP263.
1. Ismat FA, Ma X, Wang Z, et al. Phase I Assessment of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Oral Protease-activated Receptor-4 Antagonist BMS-986120. Stroke 2016;47:ATMP91.
1. Wilson SJ, Ismat FA, Narayan H, et al. Protease-Activated Receptor Type 4 (PAR-4) Antagonism With BMS-986120 Selectively Inhibits Human Thrombus Formation Under Conditions of High Shear Stress. Circulation 2016;134:A18771.